Overview

A Study to Investigate the Antihypertensive Efficacy of MK0954

Status:
Completed
Trial end date:
1992-11-01
Target enrollment:
Participant gender:
Summary
After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Antihypertensive Agents
Losartan